Evotec Technologies installs plate::explorer and Opera for high throughput screening at the Genome Research Institute

Hamburg 20 October 2006Evotec Technologies GmbH, a supplier of innovative tools and technologies for life sciences and pharmaceutical drug discovery, the Genome Research Institute (GRI) at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have successfully installed at the GRI a plate::explorer with Opera High Content Screening extension to provide the scientific community with high throughput and high content screening (HTS/HCS) capabilities.


With more than 40 world-wide installations, the Opera HCS platform has grown to be the major tool for high content analysis in high throughput screening, combining the precision of confocal microscopy with the speed of primary screening. The modular plate::explorer system can be employed for uHTS, HCS, secondary screening as well as assay development. The system also enables parallel plate processing - multitasking - for highest throughput and individual plate treatment - multithreading - for unlimited assay flexibility.

"We are extremely proud to be chosen as technology provider for UC/GRI and Cincinnati Children's. We see an increasing demand for automated experimentation in academic research to cope with the high demands of pharmaceutical research. The plate::explorer is the ideal tool for such purpose because it provides biochemical and cellular assays with the desired throughput plus great flexibility. This facility, operating out of the GRI, will enhance the UC/GRI, Cincinnati Children's and researchers throughout Ohio and the region to advance their drug discovery efforts", stated Dr. Günter Bauer, Chief Business Officer at Evotec Technologies GmbH.

"Other centres concentrate heavily on basic science research, but aren't as focused or equipped to move discoveries through the necessary preclinical and clinical phases", stated George Thomas, PhD, Interim Director of the GRI and Genome Science Department at the University of Cincinnati. "Having the same equipment on site that pharmaceutical giants use themselves to further narrow drug targets puts us at quite an advantage. I'd say we are part of a pretty exclusive club."

The GRI, founded in 2001 with a gift of land and facilities from Aventis Pharmaceuticals and funded by the Ohio Third Frontier Project, is home to internationally recruited scientists researching the genetic basis of some of the world's most serious and prevalent diseases, including obesity, heart disease and cancer. Besides Cincinnati Children's Hospital Medical Center and Evotec, the GRI has partnerships with the Air Force Research Lab, Procter & Gamble, Oak Ridge National Laboratory, Ohio Supercomputer Center and Wright State University.

Evotec Technologies GmbH, subsidiary of Evotec AG, is a provider of confocal detection devices (Opera, Clarina, Insight Cell), cell handling devices (CytoClone, Cytocon) and ultra-High-Throughput Screening (uHTS) systems (EVOscreen, plate::explorer). The company¬??s product portfolio is focused on high-end technologies for automated cell biology. Its outstanding expertise in detection coupled with sophisticated automation skills, integrating hardware, software and bioware modules, makes the company a clear expert for automated cell analysis. Evotec Technologies employs 80 people, primarily at its main site in Hamburg, Germany. More company news is available in the VMW July 2004 article Vita Nuova supplies Inferno Grid to Evotec OAI to speed drug discovery process.

Leslie Versweyveld

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]